Ami Fadia
Stock Analyst at Needham
(3.88)
# 713
Out of 4,755 analysts
382
Total ratings
51.32%
Success rate
9.55%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
AXSM Axsome Therapeutics | Reiterates: Buy | $133 | $132.20 | +0.61% | 10 | Feb 10, 2025 | |
PRAX Praxis Precision Medicines | Reiterates: Buy | $150 | $84.24 | +78.06% | 8 | Feb 10, 2025 | |
NBIX Neurocrine Biosciences | Reiterates: Hold | n/a | $116.85 | - | 12 | Feb 7, 2025 | |
IMRX Immuneering | Reiterates: Buy | $12 | $1.80 | +566.67% | 13 | Feb 6, 2025 | |
DAWN Day One Biopharmaceuticals | Reiterates: Buy | $33 | $11.92 | +176.85% | 18 | Jan 13, 2025 | |
HRMY Harmony Biosciences Holdings | Reiterates: Buy | $52 | $37.74 | +37.78% | 30 | Jan 13, 2025 | |
ITCI Intra-Cellular Therapies | Downgrades: Hold | $100 | $127.56 | -21.61% | 26 | Jan 13, 2025 | |
BCYC Bicycle Therapeutics | Reiterates: Buy | $32 | $11.64 | +174.91% | 16 | Jan 13, 2025 | |
BPMC Blueprint Medicines | Reiterates: Buy | $135 | $101.57 | +32.91% | 26 | Jan 13, 2025 | |
AVDL Avadel Pharmaceuticals | Maintains: Buy | $22 → $19 | $9.00 | +111.11% | 32 | Jan 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $1.67 | +1,277.25% | 6 | Jan 2, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $207 | $129.98 | +59.26% | 26 | Dec 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $15 | $8.42 | +78.15% | 21 | Dec 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $85 | $40.11 | +111.92% | 25 | Dec 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $62 | $41.45 | +49.58% | 20 | Dec 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $7.19 | - | 18 | Nov 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $270 | $139.39 | +93.70% | 36 | Nov 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $18.49 | +51.43% | 6 | Nov 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $16 | $0.52 | +2,948.20% | 2 | Feb 1, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $27.25 | +175.23% | 7 | Jan 21, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $1.30 | +1,630.77% | 4 | Oct 1, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $24.20 | +160.33% | 5 | Sep 17, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $5 | $3.34 | +49.70% | 2 | Jan 30, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $16.59 | - | 9 | Oct 1, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.66 | +1,225.30% | 4 | Jan 3, 2018 |
Axsome Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: $133
Current: $132.20
Upside: +0.61%
Praxis Precision Medicines
Feb 10, 2025
Reiterates: Buy
Price Target: $150
Current: $84.24
Upside: +78.06%
Neurocrine Biosciences
Feb 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $116.85
Upside: -
Immuneering
Feb 6, 2025
Reiterates: Buy
Price Target: $12
Current: $1.80
Upside: +566.67%
Day One Biopharmaceuticals
Jan 13, 2025
Reiterates: Buy
Price Target: $33
Current: $11.92
Upside: +176.85%
Harmony Biosciences Holdings
Jan 13, 2025
Reiterates: Buy
Price Target: $52
Current: $37.74
Upside: +37.78%
Intra-Cellular Therapies
Jan 13, 2025
Downgrades: Hold
Price Target: $100
Current: $127.56
Upside: -21.61%
Bicycle Therapeutics
Jan 13, 2025
Reiterates: Buy
Price Target: $32
Current: $11.64
Upside: +174.91%
Blueprint Medicines
Jan 13, 2025
Reiterates: Buy
Price Target: $135
Current: $101.57
Upside: +32.91%
Avadel Pharmaceuticals
Jan 9, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $9.00
Upside: +111.11%
Jan 2, 2025
Reiterates: Buy
Price Target: $23
Current: $1.67
Upside: +1,277.25%
Dec 12, 2024
Reiterates: Buy
Price Target: $207
Current: $129.98
Upside: +59.26%
Dec 11, 2024
Downgrades: Hold
Price Target: $15
Current: $8.42
Upside: +78.15%
Dec 9, 2024
Reiterates: Buy
Price Target: $85
Current: $40.11
Upside: +111.92%
Dec 6, 2024
Maintains: Buy
Price Target: $68 → $62
Current: $41.45
Upside: +49.58%
Nov 20, 2024
Reiterates: Hold
Price Target: n/a
Current: $7.19
Upside: -
Nov 18, 2024
Downgrades: Hold
Price Target: $270
Current: $139.39
Upside: +93.70%
Nov 7, 2024
Reiterates: Buy
Price Target: $28
Current: $18.49
Upside: +51.43%
Feb 1, 2021
Maintains: Outperform
Price Target: $12 → $16
Current: $0.52
Upside: +2,948.20%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $27.25
Upside: +175.23%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $1.30
Upside: +1,630.77%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $24.20
Upside: +160.33%
Jan 30, 2019
Downgrades: Market Perform
Price Target: $12 → $5
Current: $3.34
Upside: +49.70%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $16.59
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.66
Upside: +1,225.30%